NCT05842213View on ClinicalTrials.gov

Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX

PHASE3CompletedINTERVENTIONAL
Enrollment

502

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

March 4, 2024

Study Completion Date

September 24, 2024

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

AVT05 (proposed biosimilar to golimumab)

AVT05 is a recombinant human IgG1қ mAb developed as a subcutaneous injection

BIOLOGICAL

Simponi (Golimumab)

Simponi (Golimumab) is a recombinant human IgG1қ mAb developed as a subcutaneous injection

Trial Locations (1)

4001

Rheumatology clinic, University Multiprofile Hospital for Active Treatment Kaspela, Plovdiv

All Listed Sponsors
lead

Alvotech Swiss AG

INDUSTRY